VTGN Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -6020.94% compared to Vistagen Therapeutics's net margin of --. Vistagen Therapeutics's return on equity of -45.8% beat Perspective Therapeutics's return on equity of --.

Vistagen Therapeutics has a consensus price target of $13.00, signalling upside risk potential of 485.59%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 588.65%. Given that Perspective Therapeutics has higher upside potential than Vistagen Therapeutics, analysts believe Perspective Therapeutics is more attractive than Vistagen Therapeutics.

Vistagen Therapeutics has a beta of 0.562, which suggesting that the stock is 43.775% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

Vistagen Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vistagen Therapeutics pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

Vistagen Therapeutics quarterly revenues are $234K, which are larger than Perspective Therapeutics quarterly revenues of --. Vistagen Therapeutics's net income of -$14.1M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, Vistagen Therapeutics's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics is 94.60x versus 13.53x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical has a net margin of -6020.94% compared to Vistagen Therapeutics's net margin of -80.9%. Vistagen Therapeutics's return on equity of -45.8% beat Ultragenyx Pharmaceutical's return on equity of -194.36%.

Vistagen Therapeutics has a consensus price target of $13.00, signalling upside risk potential of 485.59%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $92.35 which suggests that it could grow by 161.32%. Given that Vistagen Therapeutics has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Vistagen Therapeutics is more attractive than Ultragenyx Pharmaceutical.

Vistagen Therapeutics has a beta of 0.562, which suggesting that the stock is 43.775% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.607, suggesting its less volatile than the S&P 500 by 39.255%.

Vistagen Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vistagen Therapeutics pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

Vistagen Therapeutics quarterly revenues are $234K, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $164.9M. Vistagen Therapeutics's net income of -$14.1M is higher than Ultragenyx Pharmaceutical's net income of -$133.4M. Notably, Vistagen Therapeutics's price-to-earnings ratio is -- while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics is 94.60x versus 5.71x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

AVITA Medical has a net margin of -6020.94% compared to Vistagen Therapeutics's net margin of -62.96%. Vistagen Therapeutics's return on equity of -45.8% beat AVITA Medical's return on equity of -252.91%.

Vistagen Therapeutics has a consensus price target of $13.00, signalling upside risk potential of 485.59%. On the other hand AVITA Medical has an analysts' consensus of $17.17 which suggests that it could grow by 85.98%. Given that Vistagen Therapeutics has higher upside potential than AVITA Medical, analysts believe Vistagen Therapeutics is more attractive than AVITA Medical.

Vistagen Therapeutics has a beta of 0.562, which suggesting that the stock is 43.775% less volatile than S&P 500. In comparison AVITA Medical has a beta of 1.597, suggesting its more volatile than the S&P 500 by 59.684%.

Vistagen Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AVITA Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vistagen Therapeutics pays -- of its earnings as a dividend. AVITA Medical pays out -- of its earnings as a dividend.

Vistagen Therapeutics quarterly revenues are $234K, which are smaller than AVITA Medical quarterly revenues of $18.4M. Vistagen Therapeutics's net income of -$14.1M is lower than AVITA Medical's net income of -$11.6M. Notably, Vistagen Therapeutics's price-to-earnings ratio is -- while AVITA Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics is 94.60x versus 3.72x for AVITA Medical. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals has a net margin of -6020.94% compared to Vistagen Therapeutics's net margin of -9.24%. Vistagen Therapeutics's return on equity of -45.8% beat Vanda Pharmaceuticals's return on equity of -3.49%.

Vistagen Therapeutics has a consensus price target of $13.00, signalling upside risk potential of 485.59%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 189.86%. Given that Vistagen Therapeutics has higher upside potential than Vanda Pharmaceuticals, analysts believe Vistagen Therapeutics is more attractive than Vanda Pharmaceuticals.

Vistagen Therapeutics has a beta of 0.562, which suggesting that the stock is 43.775% less volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.720, suggesting its less volatile than the S&P 500 by 28.044%.

Vistagen Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vistagen Therapeutics pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

Vistagen Therapeutics quarterly revenues are $234K, which are smaller than Vanda Pharmaceuticals quarterly revenues of $53.2M. Vistagen Therapeutics's net income of -$14.1M is lower than Vanda Pharmaceuticals's net income of -$4.9M. Notably, Vistagen Therapeutics's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics is 94.60x versus 1.28x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.